Literature DB >> 6230884

Adverse reactions in connection with zimeldine treatment--a review.

B S Nilsson.   

Abstract

The results of clinical trials have shown that the general level of side-effects is substantially lower with zimeldine than with tricyclic antidepressants. Data from ordinary clinical usage in Sweden and the U.K. (as opposed to clinical research experience) shows a similar picture. Hypersensitivity reactions, characterized by fever, myalgia and/or arthralgia, and transient increases in transaminases, occur in approximately 1.5% of patients. In rare cases potentially serious neuropathies have been reported.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6230884     DOI: 10.1111/j.1600-0447.1983.tb11110.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  7 in total

Review 1.  A brief history of the development of antidepressant drugs: from monoamines to glutamate.

Authors:  Todd M Hillhouse; Joseph H Porter
Journal:  Exp Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.157

2.  No crossover of hypersensitivity between zimelidine and fluoxetine.

Authors:  G Chouinard; B Jones
Journal:  Can Med Assoc J       Date:  1984-11-15       Impact factor: 8.262

Review 3.  The risk-benefit assessment of antidepressant drugs.

Authors:  J A Henry; A J Martin
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Nov-Dec

Review 4.  The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs.

Authors:  Guy Chouinard
Journal:  J Psychiatry Neurosci       Date:  2006-05       Impact factor: 6.186

Review 5.  Comparative efficacy of antidepressants.

Authors:  S Kasper; J Fuger; H J Möller
Journal:  Drugs       Date:  1992       Impact factor: 9.546

6.  High incidence of multisystemic reactions to zimeldine.

Authors:  R Langlois; G Cournoyer; C de Montigny; G Caillé
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 7.  Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.

Authors:  P Benfield; R C Heel; S P Lewis
Journal:  Drugs       Date:  1986-12       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.